Code Biotherapeutics
Latest round
- Series A
Last raised
- May 2022
Total raised
- $48M
Investors
- 10
About Code Biotherapeutics
Based in the US, Code Biotherapeutics, Inc.Founded in 2020 and headquartered in Hatfield, US, Code Biotherapeutics, Inc. is dedicated to creating genetic therapies for life-threatening diseases, particularly Duchenne Muscular Dystrophy (DMD).Code Biotherapeutics specializes in the development of precision genetic medicines, utilizing its innovative 3DNA® platform. This proprietary, multivalent, synthetic DNA delivery system is crafted to tackle significant challenges associated with genetic therapy delivery, such as dose-related toxicity, immunogenicity, and off-target effects.Code Biotherapeutics generates revenue through strategic partnerships and collaborations for research and development of its genetic medicine pipeline. This includes agreements with research institutions and pharmaceutical companies that facilitate the development and commercialization of the 3DNA® delivery platform. The initiatives indicate a commitment to not only innovate new products but also expand their reach within the biotechnology sector.
Who invested in Code Biotherapeutics
10 investors across 2 rounds
See all investors in Code Biotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Code Biotherapeutics
Who invested in Code Biotherapeutics?
Code Biotherapeutics has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Code Biotherapeutics raised?
Code Biotherapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Code Biotherapeutics last raise money?
Code Biotherapeutics's most recent round on record is a Series A, in May 2022.
What does Code Biotherapeutics do?
Based in the US, Code Biotherapeutics, Inc.
Where is Code Biotherapeutics headquartered?
Code Biotherapeutics is headquartered in Hatfield, US.
Which VCs invest in companies like Code Biotherapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Code Biotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Code Biotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.